KEQU vs. EYPT, AEHR, SENS, ALNT, QTRX, QSI, NAUT, FEIM, AKYA, and SEER
Should you be buying Kewaunee Scientific stock or one of its competitors? The main competitors of Kewaunee Scientific include EyePoint Pharmaceuticals (EYPT), Aehr Test Systems (AEHR), Senseonics (SENS), Allient (ALNT), Quanterix (QTRX), Quantum-Si (QSI), Nautilus Biotechnology (NAUT), Frequency Electronics (FEIM), Akoya Biosciences (AKYA), and Seer (SEER). These companies are all part of the "measuring and control equipment" industry.
Kewaunee Scientific vs.
Kewaunee Scientific (NASDAQ:KEQU) and EyePoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.
EyePoint Pharmaceuticals received 323 more outperform votes than Kewaunee Scientific when rated by MarketBeat users. Likewise, 70.24% of users gave EyePoint Pharmaceuticals an outperform vote while only 67.94% of users gave Kewaunee Scientific an outperform vote.
In the previous week, EyePoint Pharmaceuticals had 3 more articles in the media than Kewaunee Scientific. MarketBeat recorded 4 mentions for EyePoint Pharmaceuticals and 1 mentions for Kewaunee Scientific. EyePoint Pharmaceuticals' average media sentiment score of 0.94 beat Kewaunee Scientific's score of 0.47 indicating that EyePoint Pharmaceuticals is being referred to more favorably in the news media.
EyePoint Pharmaceuticals has a consensus price target of $26.63, suggesting a potential upside of 248.95%. Given EyePoint Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe EyePoint Pharmaceuticals is more favorable than Kewaunee Scientific.
Kewaunee Scientific has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, EyePoint Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500.
32.7% of Kewaunee Scientific shares are owned by institutional investors. Comparatively, 99.4% of EyePoint Pharmaceuticals shares are owned by institutional investors. 14.2% of Kewaunee Scientific shares are owned by company insiders. Comparatively, 4.7% of EyePoint Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Kewaunee Scientific has a net margin of 9.39% compared to EyePoint Pharmaceuticals' net margin of -226.57%. Kewaunee Scientific's return on equity of 25.83% beat EyePoint Pharmaceuticals' return on equity.
Kewaunee Scientific has higher revenue and earnings than EyePoint Pharmaceuticals. EyePoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Kewaunee Scientific, indicating that it is currently the more affordable of the two stocks.
Summary
EyePoint Pharmaceuticals beats Kewaunee Scientific on 10 of the 18 factors compared between the two stocks.
Get Kewaunee Scientific News Delivered to You Automatically
Sign up to receive the latest news and ratings for KEQU and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kewaunee Scientific Competitors List
Related Companies and Tools
This page (NASDAQ:KEQU) was last updated on 1/22/2025 by MarketBeat.com Staff
